# Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)

> **NCT02940886** · PHASE3 · COMPLETED · sponsor: **Pharmacosmos A/S** · enrollment: 1512 (actual)

## Conditions studied

- Iron Deficiency Anaemia
- Iron Deficiency Anemia

## Interventions

- **DRUG:** Iron isomaltoside/ferric derisomaltose
- **DRUG:** Iron sucrose

## Key facts

- **NCT ID:** NCT02940886
- **Lead sponsor:** Pharmacosmos A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-08
- **Primary completion:** 2018-03-28
- **Final completion:** 2018-03-28
- **Target enrollment:** 1512 (ACTUAL)
- **Last updated:** 2020-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02940886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02940886, "Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02940886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*